Copley Acquisition Corp

In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” contained in our (i) Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026, and (ii) Prospectus dated April 30, 2025. As of the date of this Report, other than as set forth below, there have been no material changes with respect to those risk factors.

On June 10, 2026, we entered into a Business Combination Agreement with Ignite Proteomics, LLC (“Ignite”) and certain other parties, as more fully described in our Current Report on Form 8-K filed with the SEC on June 11, 2026. The proposed business combination is subject to numerous risks and uncertainties, including risks related to the satisfaction of closing conditions, receipt of required shareholder approvals, the level of redemptions by our public shareholders, and risks specific to the business of Ignite. There can be no assurance that the proposed business combination will be consummated on the terms or timeline currently contemplated, or at all.

A comprehensive discussion of risks related to the proposed business combination and the business of Ignite will be included in the registration statement on Form S-4 to be filed with the SEC in connection with the proposed transaction.